Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
[1] Patients should maintain realistic expectations, as skin changes may improve gradually over time as the body adjusts to its new weight
In clinical trials this translates into larger average weight loss than mono-agonist GLP-1s in adults with obesity
Your body weight before starting treatment, genetics and commitment to resistance training all influence outcomes
The American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonylurea (SU), for patients with T2D and ASCVD, stage 3 CKD, or heart failure with reduced ejection fraction [2]
US$ 24.50
US$ 25.37
US$ 21.39
